Immuneering annual free cash flow
2020
2021
2022
2023
2024
2025
Immuneering Free Cash Flow (FCF) History (IMRX)
Immuneering reported −$45.5M in free cash flow for fiscal 2025, an increase of $9.6M from the previous fiscal year.
View full Immuneering company overviewImmuneering free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$45.5M | $9.6M | — | — |
| 2024 | 2024-12-31 | −$55.1M | −$5.8M | — | — |
| 2023 | 2023-12-31 | −$49.3M | −$4.5M | — | — |
| 2022 | 2022-12-31 | −$44.8M | −$13.9M | — | −14148.44% |
| 2021 | 2021-12-31 | −$30.9M | −$16.2M | — | −1486.17% |
| 2020 | 2020-12-31 | −$14.7M | — | — | −634.83% |
Immuneering quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$16.5M | −$7.1M | — | — |
| Q1 2026 | 2026-03-31 | −$18.5M | −$4.4M | — | — |
| Q4 2025 | 2025-12-31 | −$10.0M | $4.6M | — | — |
| Q3 2025 | 2025-09-30 | −$12.0M | $1.5M | — | — |
| Q2 2025 | 2025-06-30 | −$9.4M | $2.1M | — | — |
| Q1 2025 | 2025-03-31 | −$14.1M | $1.4M | — | — |
| Q4 2024 | 2024-12-31 | −$14.5M | −$2.6M | — | — |
| Q3 2024 | 2024-09-30 | −$13.5M | −$1.4M | — | — |
| Q2 2024 | 2024-06-30 | −$11.6M | −$723,524 | — | — |
| Q1 2024 | 2024-03-31 | −$15.5M | −$1.1M | — | — |
| Q4 2023 | 2023-12-31 | −$11.9M | −$128,203 | — | — |
| Q3 2023 | 2023-09-30 | −$12.1M | −$1.1M | — | — |
| Q2 2023 | 2023-06-30 | −$10.8M | −$1.2M | — | — |
| Q1 2023 | 2023-03-31 | −$14.4M | −$2.0M | — | — |
| Q4 2022 | 2022-12-31 | −$11.8M | −$2.6M | — | −2597344.18% |
| Q3 2022 | 2022-09-30 | −$11.0M | −$2.0M | — | −28701.08% |
| Q2 2022 | 2022-06-30 | −$9.6M | −$3.2M | — | −10182.56% |
| Q1 2022 | 2022-03-31 | −$12.4M | −$6.2M | — | −6748.08% |
| Q4 2021 | 2021-12-31 | −$9.3M | −$5.8M | — | −4880.00% |
| Q3 2021 | 2021-09-30 | −$9.0M | — | — | −1876.25% |
| Q2 2021 | 2021-06-30 | −$6.5M | — | — | −978.31% |
| Q1 2021 | 2021-03-31 | −$6.2M | — | — | −822.83% |
| Q3 2020 | 2020-09-30 | −$3.5M | — | — | −511.54% |
Immuneering free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$14.7M to −$45.5M, a net decrease of $30.8M. Immuneering's latest reported quarter, Q2 2026, generated −$16.5M in free cash flow, a decrease of $7.1M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Immuneering filings at SEC.gov ↗